| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90d863c6ac1f6b17c8da3f59358e97ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec7d510bdd2c702502309a44e126ac21 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2018-12-14^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1adb2524f3735d6423d1c6f8707433bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fb4804fa0c3700bf8dc34508369c096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e2c4e80035449562f87506ee5275624
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46718f3f34fbdaa4798f9f69a1b6d9d0 |
| publicationDate |
2019-06-20^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019118793-A2 |
| titleOfInvention |
Subject-specific tumor inhibiting cells and the use thereof |
| abstract |
This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-bv -/- TICs). The Cbl-b -/- TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111662871-A |
| priorityDate |
2017-12-14^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |